Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Fredun Pharmaceuticals Ltd.
Change Company   
BSE Code 539730
ISIN Demat INE194R01017
Book Value 333.71
NSE Code NA
Dividend Yield % 0.04
Market Cap 8069.56
P/E 27.92
EPS 61.21
Face Value 10  
29-Nov-2025 Fredun Pharmaceuticals informs about appointment...
13-Oct-2025 Fredun Pharmaceuticals launches ‘Snacky Jain’
13-Oct-2025 Fredun Pharmaceuticals informs about certificate
13-Oct-2025 Fredun Pharmaceuticals zooms on launching ‘Snacky...
10-Oct-2025 Fredun Pharmaceuticals moves up on acquiring Wagr
09-Oct-2025 Fredun Pharmaceuticals acquires Wagr
26-Sep-2025 Allotment of Convertible warrants
01-Jul-2025 Fredun Pharmaceuticals moves up as its arm acquir...
30-Jun-2025 Fredun Pharmaceuticals’ arm acquires controlling ...
22-May-2025 Fredun Pharmaceuticals informs about board meeti...
10-Apr-2025 Fredun Pharmaceuticals secures tender from TNMSC ...
03-Apr-2025 Fredun Pharmaceutical informs about press release
12-Mar-2025 Fredun Pharmaceuticals forays into large animal v...
12-Mar-2025 Fredun Pharmaceuticals moves higher after forayin...
03-Feb-2025 Fredun Pharmaceuticals installs second Italian Tu...
Page 1 of 1
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.